Prothena Corporation plc provided earnings guidance for the year 2023. The company continues to expect the full-year 2023 net cash used in operating and investing activities to be $213 million to $229 million and expects to end the year with approximately $512 million in cash, cash equivalents and restricted cash (midpoint). The estimated full-year 2023 net cash used in operating and investing activities is primarily driven by an estimated net loss of $250 million to $275 million, which includes an estimated $46 million of non-cash share-based compensation expense.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.95 USD | -0.45% | -11.84% | -45.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.10% | 1.08B | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- PRTA Stock
- News Prothena Corporation plc
- Prothena Corporation plc Provides Earnings Guidance for the Year 2023